moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Changes in Registrant’s Certifying Accountant

Item 4.01

(a) On February 21, 2017, the Audit Committee of the Board of
Directors (the Audit Committee) of Moleculin Biotech, Inc. (the
Company), dismissed GBH CPAs, PC (GBH) as its independent
registered public accounting firm, effective as of such date.

The report of GBH on the Companys financial statements as of
December 31, 2015 and for the period from July 28, 2015
(inception) to December 31, 2015 and the financial statements of
Moleculin, LLC as of and for the years ended December 31, 2015
and 2014 did not contain an adverse opinion or disclaimer of
opinion, and was not qualified or modified as to uncertainty,
audit scope, or accounting principles, other than an explanatory
paragraph relating to the Companys ability to continue as a going
concern. During the year ended December 31, 2015 and through
February 21, 2017 there were no: (1) disagreements (as defined in
Item 304(a)(1)(iv) of Regulation S-K and the related instructions
to Item 304 of Regulation S-K) with GBH on any matter of
accounting principles or practices, financial statement
disclosure, or auditing scope or procedures, which disagreements,
if not resolved to the satisfaction of GBH, would have caused GBH
to make reference to the matter in its report on the financial
statements for such year.

The Company has provided GBH with a copy of the foregoing
disclosures and requested that it furnish a letter to the
Securities and Exchange Commission stating whether or not it
agrees with the above statements, and, if not, stating the
respects in which it does not agree. A copy of such letter is
filed as Exhibit 16.1 to this Current Report on Form 8-K.

(b) On February 21, 2017, the Audit Committee approved the
appointment of Grant Thornton LLP (GT) as the Companys
independent registered public accounting firm for the fiscal year
ended December 31, 2016.

During the period from July 28, 2015 (inception) to December 31,
2015, and through February 21, 2017, neither the Company nor
anyone on their behalf consulted with GT with respect to either
(i) the application of accounting principles to a specific
transaction, either completed or proposed, or the type of audit
opinion that might be rendered on the Companys financial
statements, and neither written nor oral advice was provided to
the Company that GT concluded was an important factor considered
by the Company in reaching a decision as to any accounting,
auditing or financial reporting issue; (ii) any matter that was
either the subject of disagreement (as defined in Item
304(a)(1)(iv) of Regulation S-K and the related instructions to
Item 304 of Regulation S-K) or a reportable event (as described
in Item 304(a)(1)(v) of Regulation S-K).

(d)Exhibits.

About moleculin biotech, INC. (NASDAQ:MBRX)

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.

moleculin biotech, INC. (NASDAQ:MBRX) Recent Trading Information

moleculin biotech, INC. (NASDAQ:MBRX) closed its last trading session up +0.01 at 1.13 with 271,168 shares trading hands.